So you’re saying that Nader isn’t telling us t
Post# of 148168
(Total Views: 449)
Posted On: 09/21/2021 8:16:34 PM
So you’re saying that Nader isn’t telling us the truth? Because if he paid a premium like he said then don’t you think we should get the value from paying the extra amount for a quick trial results? Wouldn’t you say this is out of Naders hands really. This is all based on a start of trial to finishing of a trial that was promised by Albert Einstein our new CRO. So are we not expecting them to hold to their word of how fast they could progress the trials based on their word? This isn’t about Nader and a date.
Nader said completion of enrollment of trials +28 days. That’s all Nader said. The information of the 2 to 2 1/2 months is from a reputable CRO. Thank god it’s not Amerex and we hope we can take our new CRO at their word.
The time for analysis is another subject but my guess is that it is Biomm that grabs the results and starts the EUA or equivalent for Brazil first as they share the results with us. This is the interim results if p-value and efficacy is achieved.
If not we wait for completion of the trial and hope those results are good enough as we had hoped. The real question is a time issue of a couple of weeks and use the trials completion results. What would be a respectable return on analysis 2 weeks? 4 weeks? For either interim or trial completion…
CDIDDY… We know you took it hard when the CD-12 trial didn’t show as well as we all hoped. But I just have to say you’re favoring the pessimistic side and that look doesn’t look good on you. You are not your old self and the level headed person is leaning more one way than the way you use to lean. Maybe it’s just me that see’s this. But dude… you need to lighten up a little. I have real good feelings on these trials and the timeline is what it is. It’s not a Nader promise. It’s a group of new partners that have a shit load more experience in the game of drug approvals. We have a good size pharmaceutical in Biomm getting this done for us. I expect excellence from our new partners. Timely professionalism and great results. I hope you see the difference from now to a year ago. We are in a much better position.
Nader said completion of enrollment of trials +28 days. That’s all Nader said. The information of the 2 to 2 1/2 months is from a reputable CRO. Thank god it’s not Amerex and we hope we can take our new CRO at their word.
The time for analysis is another subject but my guess is that it is Biomm that grabs the results and starts the EUA or equivalent for Brazil first as they share the results with us. This is the interim results if p-value and efficacy is achieved.
If not we wait for completion of the trial and hope those results are good enough as we had hoped. The real question is a time issue of a couple of weeks and use the trials completion results. What would be a respectable return on analysis 2 weeks? 4 weeks? For either interim or trial completion…
CDIDDY… We know you took it hard when the CD-12 trial didn’t show as well as we all hoped. But I just have to say you’re favoring the pessimistic side and that look doesn’t look good on you. You are not your old self and the level headed person is leaning more one way than the way you use to lean. Maybe it’s just me that see’s this. But dude… you need to lighten up a little. I have real good feelings on these trials and the timeline is what it is. It’s not a Nader promise. It’s a group of new partners that have a shit load more experience in the game of drug approvals. We have a good size pharmaceutical in Biomm getting this done for us. I expect excellence from our new partners. Timely professionalism and great results. I hope you see the difference from now to a year ago. We are in a much better position.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼